<DOC>
	<DOCNO>NCT00998426</DOCNO>
	<brief_summary>HepaGam B Hepatitis B Immune Globulin ( HBIG ) solution contain 10 % maltose , could possibly interfere measurement glucose level use glucose non-specific test . The purpose study determine whether use HepaGam B HBIG show increase glucose level body use non-specific glucose monitoring , well specific glucose monitoring . The sponsor believe medication cause significant increase glucose level body measure glucose non-specific test .</brief_summary>
	<brief_title>Evaluating Blood Glucose Levels During Infusion With HepaGam B ( HBIG ) Post-liver Transplant Patients</brief_title>
	<detailed_description>BACKGROUND : Hepatitis B Immune Globulin ( HBIG ) use post liver transplantation ( OLT ) hepatitis B surface antigen-positive recipient prevent recurrence hepatitis B . One formulation HBIG , HepaGam B , contain disaccharide maltose , potentially falsely elevate glucose reading glucose nonspecific point care ( GNSPOC ) test use , glucose dehydrogenase pyrroloquinolinequinone ( GDH-PQQ ) -based method . This result inappropriate administration antidiabetic agent resultant episode clinically significant hypoglycemia . Glucose specific point care ( GSPOC ) testing , glucose oxidase-based method , however , affect presence maltose . The purpose study determine significant difference glucose reading use GSPOC GNSPOC monitoring device HBIG administration . METHODS : This nonrandomized , prospective study evaluate patient receive maintenance HBIG therapy 3 month post liver transplantation . Blood glucose level subject analyze GSPOC GNSPOC device specific time around HBIG administration .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>write informed consent HBsAG positive candidate HBV relate liver transplant place HepaGam B therapy prevention HBV recurrence acute phase ( immediately post operative ) long term maintenance phase least 18 year age unable unwilling provide write informed consent concomitant administration maltose contain product dietary supplement , dietary aid , IVIG , external peritoneal dialysis solution arm concomitant administration corticosteroid long term maintenance phase pregnancy , determine pregnancy test administer consent sign</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hepatitis B immune globulin</keyword>
	<keyword>HBIG</keyword>
	<keyword>HepaGam B</keyword>
	<keyword>orthotopic liver transplant</keyword>
</DOC>